Liquid coagulation function test reagent containing liposomes

By controlling the particle size of liposomes, the problem of differences between batches of coagulation function detection reagents is solved, and high-precision coagulation function detection is achieved, ensuring the stability and consistency of the reagent.

CN112368580BActive Publication Date: 2024-11-08PHC CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980045593.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-07-06
Filing Date
2019-07-05
Publication Date
2024-11-08
Estimated Expiration
2039-07-05

AI Technical Summary

Technical Problem

There are differences between existing coagulation function detection reagents between production batches, which affects the accuracy and reliability of diagnosis. In particular, the particle size uniformization of phospholipids in APTT reagents is difficult to completely eliminate the differences between batches.

Method used

By controlling the particle size of liposomes, the accumulated accumulated value from 351 nm to the maximum particle size value is more than 0% and less than 35%, so as to reduce the difference between production batches. Mixed phospholipids, dispersion, and liposomes are formed through Particle size adjustment means to prepare uniform liposomes.

Benefits of technology

The difference between batches of coagulation function detection is significantly reduced, the high accuracy and reliability of the detection is improved, and the stability and consistency of coagulation function detection reagents are ensured.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0002885961740000011
    Figure HDA0002885961740000011
  • Figure HDA0002885961740000012
    Figure HDA0002885961740000012
  • Figure HDA0002885961740000013
    Figure HDA0002885961740000013
Patent Text Reader

Abstract

The present invention provides a liquid coagulation function detection reagent containing liposomes with small differences between production batches. The cumulative value of the liposome from 351nm to the maximum particle size is more than 0% and less than 35% of the cumulative value of the entire liposome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a liquid blood coagulation function detection reagent containing liposomes. Background Art

[0002] In clinical examinations, examinations for examining pathological coagulation function caused by the activity of coagulation factors are routinely performed. Among them, an examination method using liposomes containing a double-layer membrane composed of phospholipids is used. Examples include activated partial thromboplastin time (APTT) assay, prothrombin time (PT) assay, quantitative coagulation factor assay using APTT assay or PT assay, complex factor (complex factor) assay, quantitative anticoagulant assay, and the like.

[0003] Liposomes are bilayer membranes composed of phospholipids from organisms. Liposomes are used in pharmaceutical preparations, cosmetic materials, in vitro diagnostic reagents, drug delivery systems, etc.

[0004] Blood coagulation reaction is realized by the cascade reaction of multiple coagulation factors, but most of its reactions are carried out on the membrane surface of phospholipids. In terms of the hydrophilic group part of phospholipids and coagulation factors, the negative charge of phosphatidylserine (PS) or phosphatidylglycerol (PG) etc. is important. On the other hand, the fluidity of the phospholipid membrane caused by the fatty acid side chain of phospholipids is known to have a greater impact on the coagulation reaction. It is also known that the activity of liposomes containing unsaturated fatty acids that enhance fluidity is high.

[0005] Physiological hemostasis includes the extrinsic coagulation pathway initiated by the binding of tissue factor (TF) exposed to the injured area and activated factor VII, and the intrinsic coagulation pathway initiated independently of TF. Bleeding or pathological thrombosis formation is considered to be caused by the extrinsic coagulation pathway. APTT reproduces this reaction in a test tube, adds reagents to the plasma to be tested, and measures the time it takes for thrombin generated by the activation of each coagulation factor to convert fibrinogen into fibrin. APTT detects abnormalities in endogenous factors (factors XII, XI, IX, VIII, X, V, II, and fibrinogen). It is also used for quantification of endogenous coagulation factor activity as an accurate detection of APTT abnormalities, detection of acquired hemophilia and lupus anticoagulants, coagulation correction tests as differential tests, or monitoring of heparin administration.

[0006] The performance required for APTT includes high sensitivity to coagulation factors or anticoagulants such as heparin. However, since APTT is a test that requires diagnosis based on the absolute value of the clotting time, it is more likely to produce differences between production batches than in a test that requires the usual preparation of a calibration curve to obtain a diagnostic value. Therefore, as a performance that is highly desired clinically, it is particularly necessary that the differences between production batches of the reagent be small.

[0007] Regarding the differences between production batches of APTT, various studies have been implemented before. In the existing APTT reagent, phospholipids from natural sources such as soybeans are extracted and used to make APTT reagents. By converting phospholipids from natural sources into synthetic products, uniform phospholipids can be obtained, which helps to reduce the differences between production batches (non-patent literature 1). However, the differences between production batches have not been completely eliminated, and it can be said that there is still room for improvement in response to clinical needs.

[0008] For example, Patent Document 1 records that the particle size of the liposomes is made uniform by filtering with a 0.6 μm polycarbonate film, thereby obtaining a solution containing liposomes. This is an operation before reconstructing tissue factor into synthetic liposomes and before freeze drying, so it is difficult to recognize that the final product can show the effect of making the particle size uniform by filtering with a polycarbonate membrane. In addition, the effect shown in Patent Document 1 is aimed at suppressing the variation (difference) of the measured value of the prothrombin time before and after freeze drying, and the absolute value of the coagulation time of each production batch is not controlled.

[0009] Prior art literature

[0010] Patent Literature

[0011] Patent Document 1: Japanese Patent Application Publication No. 2017-181265

[0012] Non-patent literature

[0013] Non-patent document 1: Okuda Masahiro, Kikukawa Norihiro, and Uemura Yasun, "Synthetic Lipid Application and New APTT Test Methods", Journal of the Japanese Society of Hematology, February 28, 2002, Volume 3, No. 1, p. 124-131, Don't brush Summary of the invention

[0014] Technical Problems to be Solved by the Invention

[0015] The present invention is completed in view of the above problems, and provides a liquid coagulation function detection reagent containing liposomes with small differences between production batches.

[0016] Technical means to solve technical problems

[0017] The inventors of the present application have repeatedly and carefully studied the above technical problems, and found that, contrary to previous expectations, the coefficient of variation between batches varies greatly due to the particle size of the liposomes. Based on this discovery, the present invention successfully manufactures a liquid coagulation function detection reagent containing liposomes with small differences between batches by controlling the particle size of the liposomes in such a way that the cumulative cumulative value from 351 nm to the maximum particle size value of the liposomes is greater than 0% and less than 35% of the cumulative cumulative value of the entire liposomes.

[0018] That is, the present invention relates to the following contents.

[0019] [1] A liquid reagent for detecting blood coagulation function, comprising liposomes, wherein the cumulative value of the liposome from 351 nm to the maximum particle size is greater than 0% and less than 35% of the cumulative value of the liposome as a whole.

[0020] [2] The reagent according to [1], wherein the reagent is an activated partial thromboplastin time detection reagent, a prothrombin time detection reagent, a complex factor detection reagent, a specific factor activity detection reagent, or a coagulation factor inhibitor detection reagent.

[0021] [3] A method for producing a liquid coagulation function detection reagent containing liposomes, comprising:

[0022] (Step A): a step of mixing phospholipids; (Step B): a step of forming liposomes by dispersing the mixed phospholipids in an aqueous solution; and (Step C): a step of preparing uniform liposomes from the liposomes using a liposome particle size adjustment means, wherein the cumulative value of the uniform liposome from 351 nm to the maximum particle size value is greater than 0% and less than 35% of the cumulative value of the entire liposome.

[0023] [4] A method for reducing the difference between production batches of a liquid coagulation function detection reagent, which is a method for reducing the difference between production batches of a liquid coagulation function detection reagent containing liposomes, wherein the cumulative cumulative value of the liposome from 351 nm to the maximum particle size value is greater than 0% and less than 35% of the cumulative cumulative value of the liposome as a whole.

[0024] Effects of the Invention

[0025] According to the present invention, in a blood coagulation function detection reagent containing phospholipids and the phospholipids forming liposomes, the difference between production batches is reduced, thereby achieving a significant effect of enabling high-precision blood coagulation function detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 It is a graph showing the particle size distribution of liposome 1 (Example 2) and liposome 2 (Comparative Example 1).

[0027] Figure 2 To show Figure 1 Shown is a graph of the cumulative scattered intensity distribution of Liposome 1 (Example 2).

[0028] Figure 3 To show Figure 1 Shown is a graph of the cumulative scattered intensity distribution of Liposome 2 (Comparative Example 1).

[0029] Figure 4 This is a graph showing the results of the coefficient of variation (CV value) of each batch calculated by performing ATPP measurement using the APTT reagent "Example 2" and the APTT reagent "Comparative Example 1".

[0030] Figure 5 It is a graph showing the particle size distribution of liposome 3 (Example 5) and liposome 4 (Comparative Example 2).

[0031] Figure 6 To show Figure 5 Shown is a graph of the cumulative scattered intensity distribution of Liposome 3 (Example 5).

[0032] Figure 7 To show Figure 5 Shown is a graph of the cumulative scattered intensity distribution of Liposome 4 (Comparative Example 2).

[0033] Figure 8 This is a graph showing the results of the coefficient of variation (CV value) of each batch calculated by performing ATPP measurement using the APTT reagent (Example 5) and the APTT reagent (Comparative Example 2).

[0034] Fig. 9 It is a graph showing the particle size distribution of liposome 5 (Comparative Example 3).

[0035] Fig.10 To show Fig. 9 Shown is a graph of the cumulative scattered intensity distribution of Liposome 5 (Comparative Example 3). DETAILED DESCRIPTION

[0036] (Liposome)

[0037] The liposomes that can be used in the present invention can be prepared by a known method except that the particle size of the liposome is prepared so that the cumulative value from 351 nm to the maximum particle size is 0% or more and less than 35% of the cumulative value of the entire liposome.

[0038] The method for preparing liposomes may include, for example:

[0039] Step A: a step of mixing phospholipids;

[0040] Step B: a step of dispersing the mixed phospholipids in an aqueous solution to form liposomes;

[0041] Step C: a step of preparing uniform liposomes from a phospholipid mixed solution in which the liposomes are dispersed, using a liposome particle size adjustment means.

[0042] As process A, for example, phospholipids can be mixed to make, preferably, phospholipids are mixed and then a fat-soluble antioxidant is added or phospholipids are mixed in the presence of a fat-soluble antioxidant to make (phospholipid mixture with a fat-soluble antioxidant added). Phospholipids can be natural phospholipids or synthetic phospholipids. Those skilled in the art can appropriately select and use from known phospholipids, and in addition to phospholipids from plant or animal sources, phospholipids appropriately selected and combined from synthetic phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol and phosphatidylglycerol etc. can also be used. In addition, these phospholipids are suitable for containing unsaturated fatty acids on the fatty acid side chains. The phospholipid mixture can be made by a known method.

[0043] For example, a phospholipid film can be formed by dissolving a phospholipid in an organic solvent such as chloroform, adding 0.01 to 5.0% of a fat-soluble antioxidant such as butylated hydroxytoluene or α-tocopherol, and then removing the organic solvent.

[0044] As step B, there is a method of adding an aqueous solution to the phospholipid film to disperse the phospholipid film to form liposomes. For example, the aqueous solution includes a buffer solution (HEPES, TRIS, PBS, etc.), and may contain polymers such as proteins as appropriate.

[0045] As step C, it is possible to enumerate a method of appropriately selecting known liposome particle size adjustment means to prepare uniform liposomes that can be used in the present invention. As a liposome particle size adjustment means, any means can be used as long as the particle size of the liposome that can be used in the present invention can be formed, for example, permeation treatment of a filter, ultrasonic treatment, etc. can be enumerated. For the size, strength, time, capacity, etc. of the material and the pores, those skilled in the art can appropriately select and implement according to the target particle size.

[0046] As the permeation treatment of the filter, there can be cited permeation treatment using a polycarbonate membrane, a cellulose acetate membrane, etc. As the ultrasonic treatment, there can be cited ultrasonic treatment using a probe type ultrasonic generator, a water bath type ultrasonic generator, etc. Since the filter treatment can be prepared simply, it is preferred.

[0047] Regarding the particle size of the liposomes that can be used in the present invention, the cumulative cumulative value from 351 nm to the maximum particle size value of the liposome is greater than 0% and less than 35% of the cumulative cumulative value of the entire liposome, preferably greater than 0% and less than 30%, more preferably greater than 0% and less than 25%, further preferably greater than 0% and less than 20%, and particularly preferably greater than 0% and less than 15%.

[0048] In addition, the minimum particle size is not particularly limited as long as it is a size that the liposome can function as a scaffold, and those skilled in the art can appropriately select and prepare. In addition, the cumulative cumulative value of preferably 53nm to the minimum particle size value is more than 0% and less than 54% of the overall cumulative cumulative value, preferably more than 0% and less than 50%, more preferably more than 0% and less than 40%, further preferably more than 0% and less than 30%, and particularly preferably more than 0% and less than 20%.

[0049] In addition, the maximum particle size is preferably 650 nm or less, more preferably 600 nm or less, further preferably 50 nm to 600 nm, and further preferably 100 to 400 nm. Examples include: a minimum particle size of 0 nm or more, preferably 10 nm or more, more preferably 20 nm or more and 50 nm or less, and further preferably 30 nm or more and less than 66 nm.

[0050] As a method for manufacturing a coagulation function detection reagent that can be implemented in the present invention, except that the particle size of the liposome is prepared so that the cumulative cumulative value from 351 nm to the maximum particle size value is 0% or more and less than 35% of the cumulative cumulative value of the entire liposome, it can be implemented according to a known method for manufacturing a coagulation function detection reagent. As shown in the examples described later, by preparing the particle size of the liposome so that the cumulative cumulative value from 351 nm to the maximum particle size value is 0% or more and less than 35% of the cumulative cumulative value of the entire liposome, the difference between production batches can be reduced, so it is preferred.

[0051] The particle size of the liposome may be measured as the particle size of the liposome alone or as the particle size of the liposome in a state where other additives are added. Examples of additives include activators in APTT.

[0052] (Tissue Factor)

[0053] For tissue factors that can be used in the present invention, those skilled in the art can appropriately select and use from known tissue factors. Any of natural tissue factors or recombinant tissue factors can be used, but recombinant tissue factors are suitable. As recombinant tissue factors, tissue factors produced by hosts such as insect cells, genetically recombinant Escherichia coli or yeast infected with viruses can be used, and the virus is integrated with the gene sequence of human or animal tissue factors. Recombinant tissue factors can be made by known methods, for example, because the tissue factors expressed in the host are transmembrane proteins, which are insoluble in simple aqueous solvents, the cells expressed can be destroyed and extracted with a buffer containing a surfactant, thereby separating, and further purifying the separated tissue factors by operations such as chromatography.

[0054] (lipidated thromboplastin)

[0055] The lipidated thromboplastin that can be used in the present invention is, for example, composed of a tissue factor solution and a phospholipid mixture containing liposomes and added with a fat-soluble antioxidant (lipidated thromboplastin with added fat-soluble antioxidant). The lipidated thromboplastin can be appropriately selected and prepared by a person skilled in the art from the known methods for making lipidated thromboplastin, for example, a mixture of a tissue factor solution and a phospholipid mixture containing liposomes and added with a fat-soluble antioxidant in a molar ratio of about 1:1000 to 1:500000 can be cited to form a uniform solution. The tissue factor solution is a buffer solution containing a surfactant sufficient to dissolve the tissue factor and the phospholipid mixture containing liposomes and added with a fat-soluble antioxidant, wherein serum albumin, globulin, etc. may also be contained as protective proteins. The tissue factor solution and the phospholipid mixture containing liposomes and added with a fat-soluble antioxidant are fully mixed and dissolved, and then the surfactant is removed to form liposomes obtained from phospholipids, and the transmembrane region of the tissue factor is embedded in the phospholipid membrane, thereby preparing lipidated thromboplastin added with a fat-soluble antioxidant. The surfactant can be removed by a known dialysis method or a method using an adsorption resin.

[0056] (Liquid coagulation function test reagent and test method)

[0057] As the liquid coagulation function detection reagent that can be used in the present invention, it can be a reagent that is made into a liquid reagent by making a coagulation function detection reagent containing liposomes, for example, activated partial thromboplastin time detection reagent, prothrombin time detection reagent, complex factor detection reagent, specific factor activity detection reagent, or coagulation factor inhibitor detection reagent. Those skilled in the art can use known information to appropriately manufacture the reagent and use it.

[0058] In addition, as an embodiment of the liquid coagulation function detection reagent and detection method of the present invention, a preparation composed of multiple reagents such as a single reagent type or a double reagent type can be provided. Specifically, in the case of providing an activated partial thromboplastin time detection reagent, not only a single reagent type preparation in which liposomes as the main reaction components of the reagent and colloidal silica or an activator represented by ellagic acid and calcium ions as coagulation factor IV are mixed can be provided, but also a double reagent type preparation in which liposomes and an activator are separated from an aqueous solution of a calcium compound can be provided as a preparation with longer-term storage stability.

[0059] Alternatively, when the PT detection reagent is provided as a liquid reagent, for example, not only a single-reagent preparation in which lipidated thromboplastin (coagulation factor III) as the main reaction component of the reagent and calcium ions as coagulation factor IV are mixed can be provided, but also a double-reagent preparation in which lipidated thromboplastin and an aqueous solution of a calcium compound are separated can be provided as a preparation with longer-term storage stability.

[0060] As a first embodiment of the liquid coagulation function detection reagent and detection method of the present invention, it can be cited that it is used as an activated partial thromboplastin time detection reagent. Specifically, the activated partial thromboplastin time detection reagent can be provided by adding calcium ions at a concentration that can express coagulation activity to liposomes and colloidal silica or an activator represented by ellagic acid. In this reagent, a preservative, a pH buffer, an additive for avoiding the influence of anticoagulants that may affect PT determination, etc. can be added.

[0061] As a second embodiment of the liquid coagulation function detection reagent and detection method of the present invention, use as a PT detection reagent can be cited. Specifically, the PT detection reagent can be provided by adding calcium ions at a concentration that can express coagulation activity to lipidated thromboplastin. In this reagent, a preservative, a pH buffer, an additive for avoiding the influence of anticoagulants that may affect PT measurement, etc. can be added.

[0062] As a third embodiment of the liquid coagulation function detection reagent and detection method of the present invention, it can be listed that it is used as a complex factor detection reagent, which mixes a reagent constructed in the same manner as the PT detection reagent with plasma (plasma deficient: that is, containing factor II, factor VII and factor X as coagulation factors) from which factor V is removed, to detect the activity of factor II, factor VII and factor X.

[0063] The third liquid coagulation function detection reagent may be composed of a double reagent type in which the PT detection reagent and the deficiency plasma are prepared separately, or may be composed of a single reagent type in which the PT detection reagent and the deficiency plasma are mixed. As an example of a double reagent type, the first reagent is a PT detection reagent and the second reagent is deficiency plasma, and the specimen is reacted with the first reagent and then reacted with the deficiency plasma for measurement. As an example of a single reagent type, a reagent composed of a mixture of the PT detection reagent and the deficiency plasma can be cited, and the reagent is reacted with the specimen for measurement. A person skilled in the art may appropriately select or adopt any reagent composition for implementation.

[0064] As a fourth embodiment of the liquid coagulation function detection reagent and detection method of the present invention, a specific factor activity detection reagent can be listed, which is used as a specific factor activity detection reagent. The specific factor activity detection reagent is a reagent constructed in the same manner as the PT detection reagent and a factor-deficient plasma lacking any factor in the coagulation factor (factor II, factor V, factor VII and factor X) to detect the specific factor activity. For example, by combining factor VII-deficient plasma (i.e., containing factor II, factor V and factor X as coagulation factors) with a PT detection reagent, the activity of factor VII of the specimen to be tested can be measured. In addition, by combining factor II-deficient plasma (i.e., containing factor V, factor VII and factor X as coagulation factors) with a PT detection reagent, the activity of factor II of the specimen to be tested can be measured. In addition, by combining factor X-deficient plasma (i.e., containing factor II, factor V and factor VII as coagulation factors) with a PT detection reagent, the activity of factor X of the specimen to be tested can be measured.

[0065] The fourth liquid coagulation function detection reagent may be composed of a double reagent type in which the PT detection reagent and the deficiency plasma are prepared separately, or may be composed of a single reagent type in which the PT detection reagent and the deficiency plasma are mixed. As an example of a double reagent type, a first reagent is deficiency plasma, and a second reagent is a PT detection reagent, and a specimen is reacted with the first reagent, and then reacted with the second reagent for measurement. As an example of a single reagent type, a reagent in which a PT detection reagent and deficiency plasma are mixed can be cited, and a reagent is reacted with a specimen for measurement. A person skilled in the art may appropriately select or adopt any reagent composition for implementation.

[0066] The fifth embodiment of the liquid blood coagulation function detection reagent and detection method of the present invention can be implemented in the same manner as the third embodiment except that the specimen used as the object is different. It can be listed that it can also be used as a blood coagulation factor inhibitor detection reagent, which is constructed in the same manner as the PT detection reagent and detects the presence of a blood coagulation factor inhibitor in plasma.

[0067] The fifth liquid coagulation function detection reagent may be composed of a double reagent type in which the PT detection reagent and the deficiency plasma are prepared separately, or may be composed of a single reagent type in which the PT detection reagent and the deficiency plasma are mixed. As an example of the double reagent type, the first reagent is the PT detection reagent and the second reagent is the deficiency plasma, and the specimen is reacted with the first reagent and then reacted with the deficiency plasma for measurement. As an example of the single reagent type, a reagent in which the PT detection reagent and the deficiency plasma are mixed can be cited, and the reagent is reacted with the specimen for measurement. Those skilled in the art may appropriately select or adopt any reagent composition for implementation.

[0068] The activity of each factor can be examined by evaluating the time (clotting time) to observe fibrin formation (clotting) or evaluating the time (%) relative to standard plasma. A person skilled in the art can appropriately select an evaluation method according to the purpose.

[0069] (Tested specimens)

[0070] As the specimens that can be used in the present invention, according to known information, for example, blood, plasma obtained from blood, etc. can be listed. For example, plasma obtained from the blood of the test subject, control plasma, and mixtures thereof can be used. As control plasma, normal plasma, plasma for precision control, etc. can be used. Normal plasma can be plasma obtained from the blood of healthy people, or commercially available normal plasma.

[0071] Example

[0072] Hereinafter, the present invention will be specifically described by way of examples, but these examples are not intended to limit the scope of the present invention.

[0073] 《Example 1: Preparation of phospholipid mixture 1》

[0074] Dioleoylphosphatidylcholine, dioleoylphosphatidylethanolamine and dioleoylphosphatidylserine (all purchased from NOF CORPORATION) were mixed in a weight ratio of 4:3:3 and dissolved in chloroform to form a phospholipid solution. Then, a fat-soluble antioxidant butylated hydroxytoluene (BHT: purchased from WAKO) was added in a weight ratio of 0.05% relative to the phospholipid, and the solution was desolventized and dried using an evaporator to obtain a phospholipid mixture to which the fat-soluble antioxidant was added.

[0075] 《Example 2: Preparation of liposome 1》

[0076] A buffer solution (10 mmol / L HEPES, 20 mmol / L sodium chloride, pH 7.5) was added to the phospholipid mixture obtained in Example 1 and stirred to disperse the phospholipid mixture in the buffer solution.

[0077] The dispersion was passed through a polycarbonate membrane with a pore size of 200 nm 10 times to unify the particle size. The solution was diluted 50 times with a buffer (10 mmol / L HEPES, 20 mmol / L sodium chloride, 1% polyethylene glycol, pH 7.5) to prepare liposome 1. The same operation was performed three times to obtain three batches.

[0078] 《Comparative Example 1: Preparation of Liposome 2》

[0079] A buffer solution (10 mmol / L HEPES, 20 mmol / L sodium chloride, pH 7.5) was added to the phospholipid mixture obtained in Example 1 and stirred to disperse the phospholipid mixture in the buffer solution.

[0080] This solution was diluted 50-fold with a buffer (10 mmol / L HEPES, 20 mmol / L sodium chloride, 1% polyethylene glycol, pH 7.5) to prepare liposome 2. The same operation was performed three times to obtain three batches.

[0081] 《Example 3: Study on the usefulness of liposomes 1》

[0082] 《Particle size distribution measurement 1》

[0083] The particle size distribution of liposome 1 and liposome 2 obtained in Example 2 and Comparative Example 1 was measured using a dynamic light scattering method (OTSUKA ELECTRONICS CO., LTD PHOTAL ELSZ). The results are shown in Figure 1 It can be seen that liposome 1 has a peak at 187nm and is composed of liposomes of 81nm to 658nm. In contrast, liposome 2 has a peak at 6580nm and is composed of liposomes of 152nm to at least 10000nm.

[0084] also, Figure 2 The cumulative scattered intensity distribution of liposome 1 is shown in FIG, and Figure 3 The cumulative scattered intensity distribution of liposome 2 is shown in FIG.

[0085] 《Preparation of APTT reagent 1》

[0086] Liposome 1 and liposome 2 were formulated so that the phospholipid concentration was 100 mg / mL and the colloidal silica content was 0.05%, thereby obtaining APTT reagent (Example 2) and APTT reagent (Comparative Example 1), respectively.

[0087] 《Determination of coagulation time 1》

[0088] The APTT reagent "Example 2" and the APTT reagent "Comparative Example 1" were used for the measurement. As the normal range fixed value quality control plasma, Ci-Trol 1 (Sysmex Corporation) was used as normal 1, and as the pathological range fixed value quality control plasma, Ci-Trol 2 was used as pathological 1, and Ci-Trol 3 was used as pathological 2 (all Sysmex Corporation), a total of 3 types.

[0089] The clinical testing system STACIA (LSI Medience Corporation) was used for the measurement.

[0090] The measurement parameters were as follows: sample: 50 μL, APTT reagent: 50 μL, 20 mmol / L calcium chloride aqueous solution: 50 μL, and the measurement wavelength was set to 660 nm. The measurement was performed at a multiplicity of 5, and the average value was used as APTT to calculate the coefficient of variation (CV value) of each batch.

[0091] Figure 4 The results are shown in . It can be seen that compared with the APTT reagent "Comparative Example 1", the coefficient of variation of any three batches of the normal range and pathological range of the APTT reagent "Example 2" is smaller. This result can explain that the differences between the production batches of the APTT reagent containing liposomes with large particle sizes are large.

[0092] In addition, the cumulative cumulative value from 351 nm to the maximum particle size value of liposome 2 is 85% of the cumulative cumulative value of the whole, and the cumulative cumulative value from 351 nm to the maximum particle size value of liposome 1 is 15% of the cumulative cumulative value of the whole. Therefore, it can be seen that the cumulative cumulative value from 351 nm to the maximum particle size value of the liposome particle size is good, being 15% or more and less than 85% of the cumulative cumulative value of the whole.

[0093] 《Example 4: Preparation of phospholipid mixture 2》

[0094] Dioleoylphosphatidylcholine, dioleoylphosphatidylethanolamine and dioleoylphosphatidylserine (all purchased from NOF CORPORATION) were mixed in a weight ratio of 6:2:2 and dissolved in chloroform to form a phospholipid solution. Then, a fat-soluble antioxidant butylated hydroxytoluene (BHT: purchased from WAKO) was added in a weight ratio of 0.05% relative to the phospholipid, and the solution was desolventized and dried using an evaporator to obtain a phospholipid mixture 2 to which the fat-soluble antioxidant was added.

[0095] 《Example 5: Preparation of liposome 3》

[0096] A buffer solution (10 mmol / L HEPES, 20 mmol / L sodium chloride, pH 7.5) was added to the phospholipid mixture 2 obtained in Example 4 and stirred to disperse the phospholipid mixture in the buffer solution.

[0097] The dispersion was passed through a polycarbonate membrane with a pore size of 200 nm 10 times to unify the particle size. The solution was diluted 50 times with a buffer (10 mmol / L HEPES, 20 mmol / L sodium chloride, 1% polyethylene glycol, pH 7.5) to prepare liposome 3. The same operation was performed three times to obtain three batches.

[0098] 《Comparative Example 2: Preparation of Liposome 4》

[0099] A buffer solution (10 mmol / L HEPES, 20 mmol / L sodium chloride, pH 7.5) was added to the phospholipid mixture 2 obtained in Example 4 and stirred to disperse the phospholipid mixture in the buffer solution.

[0100] The dispersion was passed through a cellulose acetate membrane with a pore size of 200 nm. The solution was diluted 50-fold with a buffer (10 mmol / L HEPES, 20 mmol / L sodium chloride, 1% polyethylene glycol, pH 7.5) to prepare liposome 4. The same operation was performed three times to obtain three batches.

[0101] 《Example 6: Study on the usefulness of liposomes 2》

[0102] 《Particle size distribution measurement 2》

[0103] The particle size distribution of liposome 3 and liposome 4 was measured using dynamic light scattering (OTSUKA ELECTRONICS CO., LTD PHOTAL ELSZ). The results are shown in Figure 5 Liposome 3 has a peak at 187 nm, while liposome 4 has a peak at 351 nm.

[0104] also, Figure 6 The cumulative scattered intensity distribution of liposome 3 is shown in FIG, and Figure 7 ] The cumulative scattering intensity distribution of liposome 4 is shown in FIG. Regarding the cumulative scattering intensity distribution, all liposomes of liposome 3 have a value of 66 nm to 432 nm, whereas all liposomes of liposome 4 have a value of 66 nm to 1232 nm.

[0105] 《Preparation of APTT reagent 2》

[0106] Liposome 3 and liposome 4 were formulated so that the phospholipid concentration was 100 mg / mL and the colloidal silica was 0.05%, respectively, to obtain APTT reagent "Example 5" and APTT reagent "Comparative Example 2".

[0107] 《Coagulation Time Determination 2》

[0108] APTT reagents were used in Example 5 and Comparative Example 2 to perform APTT assays in normal range 2, pathological range 3, and pathological range 4. Normal Control (IL Company) was used as normal range fixed value quality control plasma, and Low Abnormal Control and High Abnormal Control (IL Company) were used as pathological range fixed value quality control plasma for APTT assays.

[0109] The clinical testing system STACIA (LSI Medience Corporation) was used for the measurement.

[0110] The measurement parameters were as follows: sample: 50 μL, APTT reagent: 50 μL, 20 mmol / L calcium chloride aqueous solution: 50 μL, and the measurement wavelength was set to 660 nm. The measurement was performed at a multiplicity of 3, and the average value was used as APTT to calculate the coefficient of variation (CV value) of each batch.

[0111] Figure 8 The results are shown in . It can be seen that compared with the APTT reagent "Comparative Example 2", the coefficient of variation of any three batches of the normal range and pathological range of the APTT reagent "Example 5" is smaller. This result can explain that the differences between the production batches of the APTT reagent containing liposomes with large particle sizes are large.

[0112] In addition, the cumulative cumulative value from the peak value 351 nm to the maximum particle size value of liposome 4 is 35% of the cumulative cumulative value of the whole, and the cumulative cumulative value from 351 nm to the maximum particle size value is 0% of the cumulative cumulative value of the whole in the case of liposome 3. Therefore, it can be seen that the cumulative cumulative value from 351 nm to the maximum particle size value is good, being 0% or more and less than 35% of the cumulative cumulative value of the whole.

[0113] Liposomes provide a reaction site for each coagulation factor, but since they do not participate in the reaction itself, it is believed that regardless of their size, as long as they are liposomes of a certain size, they will show a certain reactivity. However, a surprising result is that the coefficient of variation between batches varies greatly depending on the size (particle diameter) of the liposomes.

[0114] 《Comparative Example 3: Preparation of Liposome 5》

[0115] 10 mmol / L HEPES, pH 7.5 buffer solution was added to the phospholipid mixture obtained in Example 4 and stirred to disperse the phospholipid mixture in the buffer solution. The obtained solution was irradiated with ultrasound using a probe ultrasonic generator (Branson Ultrasonics, Emerson Japan, Ltd. SONIFIER 450).

[0116] Then, the liposome 5 was obtained by diluting the liposome 5 to 50 times with a buffer.

[0117] 《Particle size distribution measurement 3》

[0118] The particle size distribution of liposome 5 was measured using dynamic light scattering (OTSUKA ELECTRONICS CO., LTD PHOTAL ELSZ). The results are shown in Fig. 9Liposome 5 is composed of liposomes with a size of 19 nm to 187 nm, and has a peak at 53 nm.

[0119] also, Fig.10 The cumulative scattered intensity distribution of liposome 5 is shown in FIG. 96% of all liposomes were smaller than 123 nm.

[0120] 《Preparation of APTT reagent 3》

[0121] The liposome 5 was formulated so that the phospholipid concentration was 100 mg / mL and the colloidal silica concentration was 0.05%, respectively, to obtain an APTT reagent (Comparative Example 3).

[0122] 《Coagulation time measurement 3》

[0123] APTT reagent "Comparative Example 3" was used to perform APTT assays in normal range 2 and pathological range 3 and 4. Normal Control (IL Company) was used as normal range fixed value quality control plasma, and Low Abnormal Control and High Abnormal Control (IL Company) were used as pathological range fixed value quality control plasma for APTT assays.

[0124] The clinical testing system STACIA (LSI Medience Corporation) was used for the measurement.

[0125] The measurement parameters were as follows: sample: 50 μL, APTT reagent: 50 μL, 20 mmol / L calcium chloride aqueous solution: 50 μL, and the measurement wavelength was set to 660 nm. The measurement was performed at a multiplicity of 3, and the average value was used as APTT. The clinical testing system STACIA (LSI Medience Corporation) was used for the measurement.

[0126] Table 1 shows the clotting time. Generally, the normal range of the APTT reagent shows a clotting time of 25 seconds to 35 seconds, but the normal range in Comparative Example 3 is more than 40 seconds, which is beyond the normal range of the APTT reagent. From the above results, it is not preferred that the liposomes that can be used as the APTT reagent are too small. In addition, the minimum value of the peak value of the liposome particle size can be said to be more than 54nm.

[0127] The cumulative cumulative value from the peak value 53 nm to the minimum particle size value of liposome 5 is 54% of the total cumulative cumulative value. Therefore, it can be seen that the cumulative cumulative value from 53 nm to the minimum particle size value is good, being 0% or more and less than 54% of the total cumulative cumulative value.

[0128] In addition, as the reasons why the particle size is too small and not preferred, the following factors are mainly considered. For example, since the particle size of the liposome is small, the liposome cannot provide sufficient space as the reaction site of each coagulation factor, so the coagulation time is prolonged. Alternatively, since the measurement is performed at the same lipid concentration, when the liposome particle size is small, the number of liposome particles increases, so the probability of coagulation factors aggregating into one liposome is reduced, and the coagulation time is prolonged.

[0129] [Table 1]

[0130]

Claims

1. A liquid coagulation function detection reagent, which is a liquid coagulation function detection reagent containing liposomes, wherein: The cumulative scattering intensity distribution of the liposome from 351 nm to the maximum particle size value is greater than 0% and less than 35% of the cumulative scattering intensity distribution of the entire liposome, and the cumulative scattering intensity distribution of the liposome from 53 nm to the minimum particle size value is greater than 0% and less than 54% of the cumulative scattering intensity distribution of the entire liposome, and the cumulative scattering intensity distribution is measured by dynamic light scattering.

2. The reagent according to claim 1, wherein The reagent is an activated partial thromboplastin time detection reagent, a prothrombin time detection reagent, a complex factor detection reagent, a specific factor activity detection reagent, or a coagulation factor inhibitor detection reagent.

3. A method for preparing a liquid coagulation function detection reagent containing liposomes, comprising: Step A: a step of mixing phospholipids; Step B: a step of dispersing the mixed phospholipids in an aqueous solution to form liposomes; and Step C: A step of preparing uniform liposomes from the liposomes using a liposome particle size adjustment method, wherein the cumulative scattering intensity distribution of the uniform liposomes from 351 nm to the maximum particle size value is greater than 0% and less than 35% of the cumulative scattering intensity distribution of the liposomes as a whole, and the cumulative scattering intensity distribution of the uniform liposomes from 53 nm to the minimum particle size value is greater than 0% and less than 54% of the cumulative scattering intensity distribution of the liposomes as a whole, and the cumulative scattering intensity distribution is measured by a dynamic light scattering method.

4. A method for reducing the difference between production batches of a liquid coagulation function detection reagent, which is a method for reducing the difference between production batches of a liquid coagulation function detection reagent containing liposomes, comprising: step A: a step of mixing phospholipids; step B: a step of forming liposomes by dispersing the mixed phospholipids in an aqueous solution; and step C: a step of preparing uniform liposomes from the liposomes using a liposome particle size adjustment means, wherein the cumulative scattering intensity distribution of the uniform liposomes from 351 nm to the maximum particle size value is greater than 0% and less than 35% of the cumulative scattering intensity distribution of the entire liposome, and the cumulative scattering intensity distribution of the uniform liposomes from 53 nm to the minimum particle size value is greater than 0% and less than 54% of the cumulative scattering intensity distribution of the entire liposome, and the cumulative scattering intensity distribution is measured by a dynamic light scattering method.